Health Technology Assessment
There are no easy HTA submissions. And with our focus on the UK – including NICE – we’re well placed to help you navigate the challenges of achieving successful reimbursement.
We know the issues you’ll face.
Timing challenges based on post-Brexit regulatory processes and the aim of a NICE yes/no/optimised at the point of regulatory approval.
Lack of published data, meaning your team needs to be familiar with navigating the raw tables, figures and listings from your clinical trial. Last-minute publications requiring submission re-referencing.
And some of the most challenging and rigorous assessment criteria of cost-effectiveness globally.
We particularly excel in oncology and haematology submissions, where we can help you navigate challenges around data maturity and cost effectiveness.
Core Deliverables
- Reimbursement dossiers (NICE, SMC, NCPE)
- HTA strategy
- Landscape analysis
- Expert validation and mock negotiation
- Systematic literature review adaptation
- AMCP dossiers
- Reimbursement dossiers (NICE, SMC, NCPE)
- HTA strategy
- Landscape analysis
- Expert validation and mock negotiation
- Systematic literature review adaptation
- AMCP dossiers
Let us tell your story
Yes, HTAs are about the numbers. But they’re also about stories. About patients. And about bringing to life why this particular submission matters.
Too many times submissions lose their redthread. And we exist to make sure it’s not lost from yours.
We strive to always bring the story back to patients. To the people who’ll benefit from the technology.
And we pull that narrative across all our deliverables, from UK reimbursement dossiers to HTA landscape analyses and AMCP dossiers.
Better teams, not bigger teams
HTA requires a coordinated team effort. We collaborate with our dedicated health economic partners to provide a full, end-to-end UK HTA service, from scoping to reimbursement. We work as an integrated team, providing seamless, proactive expertise for all our clients.
"Right from our initial meeting you filled me with so much confidence due to your knowledge and expertise…the speed with which you picked up the therapy area was impressive… you were a real leader for us during this submission and worked tirelessly to ensure we remained on track"
Related Case Studies
Cross-company collaboration on a NICE HTA
Seamless collaboration with Delta Hat to deliver NICE & SMC submissions under tight timelines…
HTA scientific advice for a cell therapy in lymphoma
Supporting Global and UK pharma with early dialogue in the UK and France…
Read more from HTA scientific advice for a cell therapy in lymphoma
